Ask Tes Ai

Blood Tests Used in Lung Cancer Diagnosis

April 21, 2026Published date
April 21, 2026Last reviewed
Clinically reviewed by Physicians
Blood Tests Used in Lung Cancer Diagnosis

Outline

Blood tests used in lung cancer diagnosis include CBC, tumor markers, and liquid biopsy. Learn what each test detects, its limitations, and when it is used.

Key Takeaways

  • No blood test can confirm a lung cancer diagnosis; tissue biopsy and imaging are always required.
  • Routine blood tests, such as CBCs and metabolic panels, assess treatment eligibility and detect organ involvement.
  • Tumor markers such as CEA, CYFRA 21-1, NSE, and ProGRP are useful for monitoring but lack diagnostic accuracy when used independently.
  • Liquid biopsy analyses circulating tumor DNA in the blood and is used for biomarker testing and treatment monitoring.
  • Blood-based testing is especially useful when a tissue biopsy sample is insufficient or inaccessible.

Blood Tests Used in Lung Cancer Diagnosis

Blood tests play an important supporting role in lung cancer diagnosis, but their function is often misunderstood. No blood test currently available can confirm a lung cancer diagnosis on its own. What blood tests can do is assess overall health, detect signs of organ involvement, measure tumor markers, and, through liquid biopsy, analyze genetic information shed by tumor cells from a blood sample. Together, these tests help doctors plan next steps and guide treatment decisions.

Do Blood Tests Show Lung Cancer?

Blood tests cannot detect malignancies in organs alone, including lung cancer. However, several blood tests are regularly done within the lung cancer diagnostic pathway, each serving a distinct purpose.

Routine Blood Tests: CBC and Metabolic Panel

A complete blood count (CBC) measures red blood cells, white blood cells, and platelets. In lung cancer care, its primary role is to assess the patient's health before treatment begins. While CBC cannot detect solid organ cancers, it can detect if cancer has spread to the bone marrow and show how the body is responding to treatment. It also detects anemia or infection that may need to be addressed before surgery or chemotherapy.

A comprehensive metabolic panel (CMP) evaluates kidney function, liver function, electrolytes, and blood glucose. Elevated liver enzymes or impaired kidney function may suggest cancer has spread to these organs and can influence which treatments are safe to use. Like the CBC, this is a baseline health assessment rather than a direct cancer diagnostic.

Tumor Marker Blood Tests

Tumor markers are proteins or chemicals that are created by cancer cells or the body in response to cancer and can be measured in the blood. A review in the Journal of the Nepal Medical Association (Maharjan et al., PMC7580403) outlines the main markers used in lung cancer.

CEA (Carcinoembryonic Antigen)

CEA can be elevated in several cancers, including NSCLC. It is used to monitor treatment response and detect recurrence, but is also raised in smokers and some benign conditions, limiting its standalone diagnostic value.

CYFRA 21-1

A fragment of cytokeratin 19, CYFRA 21-1, is elevated particularly in squamous cell carcinoma and to a lesser extent in other NSCLC subtypes. It is among the more useful monitoring markers, but insufficient for definitive diagnosis.

NSE (Neuron-Specific Enolase)

NSE is most closely associated with small cell lung cancer and is used to support a suspected SCLC diagnosis and monitor treatment response.

ProGRP (Pro-Gastrin-Releasing Peptide)

ProGRP is another marker associated with SCLC, typically measured alongside NSE for the same purposes.

None of these markers is specific or sensitive enough to diagnose lung cancer independently. They are most useful for tracking disease activity and treatment response in patients already diagnosed.

Liquid Biopsy: Tumor DNA in the Blood

Liquid biopsy analyses blood for biological material released by tumor cells, including circulating tumor DNA (ctDNA) and circulating tumor cells (CTCs). It is among the most significant recent advances in blood-based lung cancer testing.

In lung cancer care, liquid biopsy is used primarily for biomarker testing, identifying actionable genetic mutations such as EGFR, ALK, ROS1, and KRAS, when tumor tissue is unavailable or insufficient. It is also used during treatment to detect emerging resistance mutations earlier than imaging, allowing oncologists to adjust therapy before clinical progression occurs.

Translational Lung Cancer Research (Wei et al., 2025) investigated the use of a four-protein panel (CEA, CYFRA 21-1, NSE, and ProGRP) in conjunction with AI as an early detection method and obtained promising results. However, this study requires more clinical research before it may be used in general practice.

The Maharjan et al. research also believes that blood-based biomarkers have tremendous potential, but no single test currently meets the standards for population-level screening. The only verified and recommended method for lung cancer screening is low-dose CT scanning.

Conclusion

Blood tests provide an essential window into the general health of the body and the particular features of a tumor, but they cannot replace a biopsy for a conclusive diagnosis. These tests provide the information needed to tailor a treatment plan, from evaluating organ function to discovering genetic markers through liquid biopsies. Blood work ensures that medical decisions are safe and precisely tailored to each patient's needs by bridging the gap between imaging and therapy.

Frequently Asked Questions

Can a blood test detect lung cancer early?

No, blood tests cannot detect lung cancer early. There are currently no blood tests that are accurate enough for independent lung cancer screening. LDCT remains the only approved screening procedure.

What is a liquid biopsy, and when is it used?

Liquid biopsy analyses circulating tumor DNA in blood to identify genetic mutations. In lung cancer, it is used for biomarker testing when tissue is unavailable and to monitor for resistance mutations during treatment.

What tumor markers are used in lung cancer?

The main markers are CEA, CYFRA 21-1, NSE, and ProGRP. None of them can detect lung cancer on their own, but they are useful for monitoring disease activity and assessing therapy response.

Why are routine blood tests ordered for lung cancer?

CBC and metabolic panels assess treatment eligibility, detect organ involvement, and establish health baselines before surgery or systemic therapy begins.

Is a liquid biopsy as accurate as a tissue biopsy?

Liquid biopsy can be very accurate at detecting specific mutations, but it may miss mutations that are present at low levels. Therefore, tissue biopsy is still used to get a definitive diagnosis. When tissue availability is limited, a liquid biopsy is done as a supplement.

Chat with Tes to get personalized medical insights on Lung Cancer

What symptoms should I look for?
Tes
Hi! I'm here to support your health journey. Here are some symptoms you should watch for a persistent cough, shortness of breath

Disclaimer: The content published on this website is intended to be a substitute for professional medical diagnosis, advice or treatment. Always seek the advice of your physician or other qualified healthcare providers with any questions you may have regarding your symptoms and medical condition for accurate medical diagnosis. Do not delay in seeking or disregarding medical advice because of something you have read on this website. Reliance on any provided medical advice completely depends on factors like age or gender.